Sanofi Shares Rise Following Deutsche Bank Upgrade, Target Price Set at €110

Sanofi shares rose 0.9% on the Paris Stock Exchange following an upgrade from Deutsche Bank analysts. The upgrade is driven by optimism over amlitelimab, a new treatment for atopic dermatitis. Sanofi remains dependent on its flagship drug Dupixent, whose patent is set to expire in 2031. Hopes for amlitelimab's phase 3 results have led Deutsche Bank to raise its recommendation and target price to €110, highlighting a 22% upside potential.

Sanofi shares experienced a 0.9% increase on the Paris Stock Exchange following an upgrade from Deutsche Bank analysts. The upgrade is driven by optimism over amlitelimab, a new treatment for atopic dermatitis [1]. The analysts at Deutsche Bank have raised their recommendation to "buy" from "hold," citing an "attractive risk/reward" ahead of key trial results for amlitelimab [1].

Sanofi remains heavily dependent on its flagship drug Dupixent, which accounts for nearly half of its pharmaceutical revenues. However, the patent for Dupixent is set to expire in 2031, creating a significant risk for the company's stock market valuation [2]. Deutsche Bank believes that amlitelimab, with its imminent Phase 3 data in atopic dermatitis, could take over from Dupixent, as this condition represents more than 70% of Dupixent's current revenues [1].

The analysts at Deutsche Bank have raised their price target for Sanofi shares to €110, a 22% increase from their previous target, citing the potential for amlitelimab to significantly boost the company's revenues [1]. The stock is currently trading at a valuation multiple of 11x earnings, which Deutsche Bank believes is relatively low compared to the risk involved [2].

The upgrade from Deutsche Bank reflects a growing optimism among investors about Sanofi's ability to diversify its revenue streams and mitigate the risks associated with the expiration of its flagship drug's patent. The upcoming Phase 3 results for amlitelimab will be closely watched by investors, as they could significantly impact the company's future prospects.

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3UP06J:0-db-upgrades-sanofi-to-buy-on-eczema-drug-potential/
[2] https://www.marketscreener.com/news/sanofi-stock-rises-on-deutsche-bank-upgrade-ce7c50d3dd88f721